Analystreport

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "sell" rating re-affirmed by analysts at Zacks Investment Research.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report